ArticlePloS one2025
Activation and proliferation profiles of M.tuberculosis specific dual functional CD4+T cells from smear negative pulmonary TB patients.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundTuberculosis is a major public health challenge in the resource-limited endemic setting of sub-Saharan Africa. The diagnostic challenge becomes worse for smear-negative TB cases. Even if efforts for non-sputum-based TB diagnostic and prognostic biomarkers, there was limited data on blood-based immunological biomarkers among smear-negative PTB patients.Therefore, we assessed the phenotypic profile (HLA-DR, CD-38, Ki-67) of M. tuberculosis specific CD4 + T cells expressing dual IFN-γ and TNF-α cytokines from smear negative PTB patients in Addis Ababa, Ethiopia. METHODOLOGY: An institutional-based longitudinal cohort study was conducted in Addis Abeba, Ethiopia, on new smear-negative PTB who were adult and HIV-negative in comparison with multiple comparator groups. A total of 149 (confirmed patients with non-TB respiratory disease -33, smear-negative TB-29, smear-positive TB-34, apparently healthy - 53) study participants was enrolled. The expression level of activation (HLA-DR, CD-38) and proliferation (Ki-67) markers from dual IFN-γ and TNF-α cytokines expressing PPD specific CD4 + T cells were assessed after surface and intracellular cytokine staining. To confirm the presence of M. tuberculosis, MGIT/LJ culture, PCR, and smear microscopy were performed.
resultThe overall level of HLA-DR and CD-38 expression in smear-negative and positive pulmonary TB patients were substantially higher than that of confirmed non-TB respiratory illness, apparently healthy QFT positive and negative study participants (p-value = 0.0127, p-value < 0.0001, p-value = 0.0043, p-value <0.0001, respectively) before commencing anti TB treatment. Also, among the smear-negative and positive pulmonary TB cohort, the expression of CD-38, HLA-DR, and HLA-DR + CD-38 + expression was reduced in the second month and six-month cohort compared with baseline data (p-value= < 0.0001, p-value = 0.00365, p -value = 0.0001, respectively).
conclusionIn this study, we found the diagnostic and prognostic potential of activation markers, particularly CD-38, in smear-negative PTB patients from dual M. tuberculosis-specific IFN-γ + TNF-α+ cytokine producing CD4 + T cells in both the presumed ex vivo and antigen-specific stimulation assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.